SmartKem, Inc. 8-K

What Happened

• SmartKem filed an 8-K on March 31, 2026 describing a private placement and related agreements entered March 30, 2026. The company agreed to sell 11,411.5 shares of newly designated Series A Convertible Preferred Stock (stated value $1,000/share) and warrants to buy up to 23,251,960 shares of common stock, with gross proceeds expected to be $9,129,200 (including the exchange of previously issued Notes valued at 120%). SmartKem also signed a Common Stock Purchase Agreement (an equity line or ELOC) giving it the right to sell up to the lesser of $500,000,000 or 19.99% of its outstanding common stock to an investor under VWAP-based mechanics.

Key Details

• Private placement: 11,411.5 Series A Preferred shares; stated value $1,000/share; initial conversion/exercise price $0.5812 per common share.
• Warrants: up to 23,251,960 shares; exercisable after 6 months until 3 years; cashless exercise if resale registration is not effective; 4.99% beneficial ownership cap (adjustable to 9.99% with notice).
• Notes exchange: $3,750,000 principal of March notes may be exchanged and was valued at 120% ($4,500,000) for the placement; those March Notes originally issued with a ~30% original issue discount.
• ELOC terms: company may sell up to the lesser of $500M or 19.99% of outstanding common; per-VWAP purchase capped at $5M; investor received 10,000 Series A shares as commitment consideration; sales priced at 90% of the lesser of (i) lowest sale price or (ii) VWAP.
• Corporate actions required: SmartKem must seek stockholder approval to increase authorized common shares from 300M to 5B, permit certain issuances under Nasdaq rules, approve a reverse split option and increase shares available under its equity plan; ELOC approval required for sales exceeding ~4.22M shares (19.99% at current counts).
• Certificate of Designations filed Mar 30, 2026 (effective upon filing): authorizes 31,412 Series A shares; conversion mechanics, dividend and liquidation seniority, 15% default dividend on triggering events and limited voting rights are specified.
• Registration rights: the company agreed to file resale registration statements for securities issued under both transactions promptly after its 2025 Form 10-K and to use best efforts to get them effective within specified timeframes (with liquidated damages for missed deadlines).

Why It Matters

• This financing materially changes SmartKem’s capital structure and is intended to provide immediate liquidity and working capital while addressing Nasdaq’s minimum stockholders’ equity deficiency. The company states the transaction brings stockholders’ equity to at least the $2.5M required under Nasdaq Rule 5550(b), and it is awaiting Nasdaq confirmation of regained compliance.
• The financing is dilutive: preferred shares convertible into common stock, warrants covering millions of shares, and an equity line that could sell up to 19.99% of the company (subject to approvals). Investors should note conversion/exercise prices, ownership caps, anti-dilution protections, and restrictions on the company’s ability to issue shares or undertake certain transactions for specified periods.
• Shareholder approvals are required for major changes (including increasing authorized common shares), so the full dilutive impact could depend on upcoming votes. The equity line provides a potential large capital source but is subject to limits, pricing mechanics and Nasdaq/stockholder approvals.